A new firm called Codiak BioSciences has secured more than $80 million in financing to create therapeutic and diagnostic products based on exosome-related technology developed at the University of Texas MD Anderson Cancer Center.

Codiak was co-founded by MD Anderson Professor Raghu Kalluri and Broad Institute President and Director Eric Lander. The firm has licensed exosome-related technology that Kalluri developed at MD Anderson, including using the small, extra-cellular vesicles to deliver therapies and analyzing their nucleic acid and protein contents for diagnostic purposes.

In addition to the licensing agreement, Codiak has signed a sponsored research agreement with MD Anderson. Codiak CEO Douglas Williams told GenomeWeb that MD Anderson holds a financial stake in the firm. Other financial details of the various agreements were not disclosed.